Overview

• WeightWatchers filed for bankruptcy on May 6, citing declining subscriptions due to the popularity of GLP-1 weight-loss drugs like Wegovy and Mounjaro.
• The company plans to submit a reorganization plan within 40 days, supported by lenders to address $1.15 billion in debt and revamp its offerings.
• Telehealth companies, including Noom and Eden, are integrating GLP-1 prescriptions into their platforms, with Noom reporting over half of its revenue from clinical drug subscriptions.
• The FDA has recently blocked sales of cheaper compounded versions of GLP-1 drugs, pressuring telehealth firms to partner with brand-name manufacturers for continued access.
• Retailers like The Vitamin Shoppe are expanding telehealth services and supplement lines to support consumers using GLP-1 treatments, reflecting the growing $150 billion market opportunity.